Rubius Therapeutics reports $32.6M loss in Q1

RUBIUS THERAPEUTICS reported a $32.6 million loss in the first quarter of 2019.
RUBIUS THERAPEUTICS reported a $32.6 million loss in the first quarter of 2019.
SMITHFIELD – Rubius Therapeutics Inc. reported a net loss of $32.6 million in the first quarter of 2019, or 42 cents per diluted share, compared with a $14.4 million loss, or $1.72 per diluted share, in the first quarter of 2018 according to a company filing Wednesday. The Cambridge, Mass., company, which specializes in allogenic…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -

No posts to display